Physician profile
Joseph Wu
NPI 1497962492
$21,375.01
in general payments reported to CMS, 2019-2025
19 companies · $9,918 in 2025
The $9,918 reported for 2025 was more than what 80% of Clinical Cardiac Electrophysiology providers received nationally (typical 2025 total: $2,477).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,292 · 2022: $553 · 2023: $1,247 · 2024: $6,364 · 2025: $9,918.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $7,500 · Travel and Lodging: $5,888 · Food and Beverage: $4,141.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $7,500.00 |
| Travel and Lodging | $5,888.32 |
| Food and Beverage | $4,141.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $14,193.49 | 2023-2025 | Amplatzer Amulet, Aveir, Tacticath Ablation Catheter, Sensor Enabled |
| Medtronic Vascular, INC. | $3,292.14 | 2019 | |
| Biosense Webster, INC. | $1,565.44 | 2023-2025 | Carto 3 |
| Cvrx, INC. | $680.44 | 2022-2025 | Barostim Neo System |
| Boston Scientific Corporation | $449.18 | 2023-2025 | Watchman Flx, Watchman |
| Cardiva Medical, INC. | $376.98 | 2024-2025 | Cardiva Vascade Mvp Vvcs 6-12f, Cardiva Vascade 6/7f Vcs, Cardiva Vascade Mvp Xl Vvcs 10-12f |
| Philips North America LLC | $174.33 | 2023 | |
| Atricure, INC. | $129.89 | 2023-2025 | Atriclip Laa Exclusion System, Atricure Cryoice Cryoablation System (Cryo2), Epi-Ease Epicardial Access System |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $87.57 | 2024-2025 | Lifevest |
| Biotronik INC. | $82.01 | 2023 | Biomonitor, Acticor 7 Vr-T Dx, Amvia Edge |
| Pfizer INC. | $72.36 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $65.81 | 2025 | |
| Janssen Pharmaceuticals, INC | $60.18 | 2024 | Xarelto |
| Inspire Medical Systems, INC. | $46.83 | 2024-2025 | Inspire |
| Alnylam Pharmaceuticals INC. | $32.65 | 2025 | Onpattro |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cordis US Corp. | $19.07 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.55 | 2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $15.58 | 2025 | Farxiga |
| Esperion Therapeutics, INC. | $13.51 | 2024 | Nexletol |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Wu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.